Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How To Handle Off-Label Promotion: A Guide From PhRMA And BIO

Executive Summary

Industry communication principles offer best practices for combating contrary evidence, refuting third-party comparative effectiveness analyses and sharing real-world evidence addressing health outcomes and costs.


Related Content

BIO Lays Ethical Foundation For Change In Off-Label Communications
Off-Label Communications: BIO Lays Ethical Foundation For Change
PhRMA/BIO Devise 'Principles' To End Off-Label Limbo
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Clinton Vs. Trump: Three Scenarios For Biopharma
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Cost Effectiveness Debate Now Features The Body Bag Argument
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
US FDA Sets Goal For Biosimilar, Drug Promotion Guidances
Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts